Lisinopril Tablet

Lisinopril Tablet

Short Description

Product Composition & Available Portfolio Range

We manufacture Lisinopril in exact, compendial strengths calibrated to support initial introductory titration up to high-potency cardioprotective maintenance blocks.

Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application
Lisinopril Anhydrous / Dihydrate USP / BP / IP 5 mg Oral Solid Uncoated Tablet Initial Titration: For low-dose introductory management, pediatric hypertension, or initial combination therapy initiation.
Lisinopril Anhydrous / Dihydrate USP / BP / IP 10 mg Oral Solid Uncoated Tablet Core Commercial Volume: Standard international baseline daily dose for mild-to-moderate chronic essential hypertension.
Lisinopril Anhydrous / Dihydrate USP / BP / IP 20 mg Oral High-Potency Solid Tablet Advanced Cardioprotection: High-strength configuration calibrated for severe heart failure management and post-infarction survival optimization.

Rate this product

Full Description

Lisinopril Tablet

Lisinopril Tablets USP / BP / IP (5 mg / 10 mg / 20 mg)

Direct-Acting Angiotensin-Converting Enzyme (ACE) Inhibitor

Healthy Life Pharma Private Limited, alongside our specialized global export and marketing division Healthy Inc, is a leading Indian manufacturer, CDMO services provider, and wholesale exporter of advanced cardiovascular, renal, and metabolic health therapeutics. We manufacture a comprehensive, internationally standardized range of Lisinopril Tablets inside our state-of-the-art, WHO–GMP certified, high-capacity solid dosage manufacturing facilities.

Serving as a primary frontline therapeutic baseline for hypertension, congestive heart failure, and post-myocardial infarction stabilization, this essential public health commodity represents a massive-volume strategic asset for national health ministries, state hospital purchasing networks, retail pharmacy distribution chains, and digital B2B marketplaces across the CIS region, Africa, LATAM, and South-East Asia.

Product Overview

This formulation operates as a "Direct Systemic Vasodilator & Renin-Angiotensin System Suppressor." It ensures long-term cardiovascular stability and kidney protection by directly stopping the production of the hormones that force blood vessels to dangerously tighten.

  • Mechanism 1 (Direct ACE Inactivation): Lisinopril physically binds to and competitively inhibits Angiotensin-Converting Enzyme (ACE). Because it is a non-prodrug, it does not require hepatic activation and acts immediately within systemic circulation.

  • Mechanism 2 (Angiotensin II Suppression): By inactivating the ACE enzyme, it completely halts the chemical conversion of Angiotensin I into Angiotensin II (a potent vasoconstrictor). This reduction in Angiotensin II concentrations forces peripheral arteries to dilate, dropping systemic vascular resistance and decreasing arterial blood pressure.

  • Mechanism 3 (Bradykinin Potentiation & Cardiac Unloading): It simultaneously blocks the breakdown of Bradykinin (a natural vasodilating peptide). The physical buildup of bradykinin further expands blood vessels and reduces aldosterone secretion, which helps clear excess sodium and fluid to significantly lower cardiac workload (preload and afterload).

Product Composition & Available Portfolio Range

We manufacture Lisinopril in exact, compendial strengths calibrated to support initial introductory titration up to high-potency cardioprotective maintenance blocks.

Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application
Lisinopril Anhydrous / Dihydrate USP / BP / IP 5 mg Oral Solid Uncoated Tablet Initial Titration: For low-dose introductory management, pediatric hypertension, or initial combination therapy initiation.
Lisinopril Anhydrous / Dihydrate USP / BP / IP 10 mg Oral Solid Uncoated Tablet Core Commercial Volume: Standard international baseline daily dose for mild-to-moderate chronic essential hypertension.
Lisinopril Anhydrous / Dihydrate USP / BP / IP 20 mg Oral High-Potency Solid Tablet Advanced Cardioprotection: High-strength configuration calibrated for severe heart failure management and post-infarction survival optimization.

Technical & Logistics Specifications

  • HS Code: 3004.90.79 (Medicaments acting on the cardiovascular system / Anti-hypertensives / ACE Inhibitors) or 3004.90.99 (General Category)

  • CAS Number: 83915-83-7 (Lisinopril Dihydrate) / 76547-98-3 (Lisinopril Anhydrous)

  • Dosage Form: Oral Solid Tablet (Precisely engineered with clear compendial score lines for exact dosage fractioning when required)

  • Packaging Configurations: 10 / 14 / 15 / 28 Tablets per Blister Strip packed in high-barrier Alu-Alu (Cold-Form Foil) or premium moisture-shield PVC/PVDC strips. Lisinopril is sensitive to atmospheric moisture; our tropicalized packaging completely shields the active core matrix, guaranteeing a stable 36-month shelf life in hot, humid Zone IVb export environments.

High-Output Granulation Technology & Quality Attributes

[ LISINOPRIL DIHYDRATE ACTIVE API ] │ ▼ [ HIGH-SHEAR WET GRANULATION ISO-BLOCK ] │ (Relative humidity strictly held below 40%) ▼ [ AUTOMATED ROTARY COMPRESSION MATRIX ] │ (Online multi-point punch weight control) ┌──────────────────────┴──────────────────────┐ ▼ ▼ [ FLUSH EXTRA-LOW TOLERANCE ] [ BIOEQUIVALENCE曲线 SYNC ] Flawless Content Uniformity (

Request a Quote

Contact our export team for product availability, packaging and documentation.

For professional procurement information only. Consult a qualified healthcare professional before using any medicine.

Rate this Product

Frequently Asked Questions

How can I request a quote for this product?

Use the enquiry form on this page or contact our export team by email or WhatsApp.

How can I confirm packaging and documentation?

Contact our export team to confirm product availability, packaging and documentation.

Related Blog Posts